, July 26
/PRNewswire/ -- Gentris Corporation, a global leader in applied clinical pharmacogenomics, announced today that they have appointed Karen Weck
, M.D., as a consulting Medical Director. Dr. Weck replaces the previous medical director to continue Gentris' CLIA program and help expand opportunities to develop new biomarkers.
"Gentris is very fortunate to have Dr. Weck join us as a consulting Medical Director," said Dawn Bordeaux, Chief Operating Officer of Gentris. "She will be an invaluable asset to our Quality Program as we continue to transition into a CLIA regulatory environment."
Dr. Weck brings over 20 years of experience to Gentris, including certified expertise in both clinical and molecular genetic pathology, which help the company to continue, and expand upon, its notable successes. Dr. Weck's distinguished professional history includes numerous research grants, a variety of honors and awards, multiple inventions, dozens of publications, and membership in several national organizations including the American Society of Human Genetics, the Association for Molecular Pathology, and the Academy of Clinical Laboratory Physicians and Scientists.
Currently, Dr. Weck is affiliated with the University of North Carolina, serving as the Director for Molecular Genetics, Associate Director of Molecular Pathology for the School of Medicine, and Associate Director of the UNC Institute of Pharmacogenomics and Individualized Therapy. She also holds positions as Associate Professor of both Genetics and Pathology and Laboratory Medicine.
Dr. Karen Weck received both her Bachelor of Science degree and Medical Degree from Duke University, and completed her residency at Washington University School of Medicine. Dr. Weck has also received board certification in molecular genetic pathology and clinical pathology from the American Board of Pathology.
About Gentris Corporation
Founded in 2001, Gentris is a leading global provider of applied clinical pharmacogenomics, an emerging field that addresses how drug response is influenced by human genetic variations. Gentris offers SNP genotyping, custom assay design and validation, expression analysis, toxicogenomics, and clinical sample bio-storage, all of which adhere to rigorous Good Laboratory Practice (GLP)and CLIA regulations. The Company maintains a strong commitment to scientific excellence, regulatory compliance, and innovative pharmacogenomics applications. Gentris is headquartered in Research Triangle Park, NC. For additional information, please visit www.gentris.com or call 919-465-0100.
SOURCE Gentris Corporation